Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma

Biochemical and Biophysical Research Communications

Volumn 425, Issue 1, 2012, Pages 45-50

  Liu, Dingxie ^a   Liu, Xuan ^b   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

Author keywords

BRAFV600E; Epigenetic regulation; Gene methylation; Melanoma; Tumor suppressor genes

Indexed keywords

MYC PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN C FOS; VEMURAFENIB;

ARTICLE; BRAFV600E GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; COMPUTER MODEL; DATA BASE; DOWN REGULATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; HUMAN; MELANOMA; METHYLATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR SUPPRESSOR GENE; UPREGULATION;

DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UP-REGULATION;

EID: 84865193393     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.046     Document Type: Article

References (23)

1. An X., Jin Y., Guo H., et al. Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor. Circulation 2009, 120:617-627.
2. Bedford M.T., Clarke S.G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 2009, 33:1-13.
3. Bonazzi V.F., Nancarrow D.J., Stark M.S., et al. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One 2011, 6:e26121.
4. Davies M.A., Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010, 29:5545-5555.
5. Esteve P.O., Chin H.G., Benner J., et al. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proc. Nat. Acad. Sci. USA 2009, 106:5076-5081.
6. Fuks F., Hurd P.J., Wolf D., et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 2003, 278:4035-4040.
7. Hou P., Liu D., Dong J., et al. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 2012, 11:286-295.
8. Jonsson G., Busch C., Knappskog S., et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 2010, 16:3356-3367.
9. Joseph E.W., Pratilas C.A., Poulikakos P.I., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Nat. Acad. Sci. USA 2010, 107:14903-14908.
10. Kaneda A., Wakazono K., Tsukamoto T., et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res. 2004, 64:6410-6415.
11. Lens M.B., Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 2004, 150:179-185.
12. McMahon M., Woods D. Regulation of the p53 pathway by Ras, the plot thickens. Biochim. Biophys. Acta 2001, 1471:M63-M71.
13. Miller A.J., Mihm M.C. Melanoma. N. Engl. J. Med. 2006, 355:51-65.
14. Momparler R.L. Cancer epigenetics. Oncogene 2003, 22:6479-6483.
15. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28:1057-1068.
16. Pratilas C.A., Taylor B.S., Ye Q., et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Nat. Acad. Sci. USA 2009, 106:4519-4524.
17. Sebolt-Leopold J.S., English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 2006, 441:457-462.
18. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Nat. Acad. Sci. USA 2005, 102:15545-15550.
19. Ueno K., Hirata H., Majid S., et al. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. Int. J. Cancer 2011, 129:2360-2369.
20. van den Hurk K., Niessen H.E., Veeck J., et al. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim. Biophys. Acta 1826, 2012:89-102.
21. Verbiest V., Montaudon D., Tautu M.T., et al. Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins. FEBS Lett. 2008, 582:1483-1489.
22. Vultur A., Villanueva J., Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin. Cancer Res. 2011, 17:1658-1663.
23. Zhao Q., Rank G., Tan Y.T., et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 2009, 16:304-311.